Next Article in Journal
The Phylogeny and Pathogenesis of Sacbrood Virus (SBV) Infection in European Honey Bees, Apis mellifera
Next Article in Special Issue
Characterization of the Lipidomic Profile of Human Coronavirus-Infected Cells: Implications for Lipid Metabolism Remodeling upon Coronavirus Replication
Previous Article in Journal / Special Issue
From SARS to MERS, Thrusting Coronaviruses into the Spotlight
Article Menu
Issue 1 (January) cover image

Export Article

Open AccessReview
Viruses 2019, 11(1), 60; https://doi.org/10.3390/v11010060

Advances in MERS-CoV Vaccines and Therapeutics Based on the Receptor-Binding Domain

1
State Key Laboratory of Pathogen and Biosecurity, Beijing Institute of Microbiology and Epidemiology, Beijing 100071, China
2
Institute of Medical and Pharmaceutical Sciences, Zhengzhou University, Zhengzhou 450052, China
3
Department of Molecular Biophysics and Biochemistry, Yale University, New Haven, CT 06520, USA
4
Lindsley F. Kimball Research Institute, New York Blood Center, New York, NY 10065, USA
*
Author to whom correspondence should be addressed.
Received: 15 December 2018 / Revised: 8 January 2019 / Accepted: 10 January 2019 / Published: 14 January 2019
(This article belongs to the Special Issue MERS-CoV)
Full-Text   |   PDF [8891 KB, uploaded 14 January 2019]   |  

Abstract

Middle East respiratory syndrome (MERS) coronavirus (MERS-CoV) is an infectious virus that was first reported in 2012. The MERS-CoV genome encodes four major structural proteins, among which the spike (S) protein has a key role in viral infection and pathogenesis. The receptor-binding domain (RBD) of the S protein contains a critical neutralizing domain and is an important target for development of MERS vaccines and therapeutics. In this review, we describe the relevant features of the MERS-CoV S-protein RBD, summarize recent advances in the development of MERS-CoV RBD-based vaccines and therapeutic antibodies, and illustrate potential challenges and strategies to further improve their efficacy. View Full-Text
Keywords: Coronavirus; MERS-CoV; spike protein; receptor-binding domain; vaccines; therapeutics Coronavirus; MERS-CoV; spike protein; receptor-binding domain; vaccines; therapeutics
Figures

Graphical abstract

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited (CC BY 4.0).
SciFeed

Share & Cite This Article

MDPI and ACS Style

Zhou, Y.; Yang, Y.; Huang, J.; Jiang, S.; Du, L. Advances in MERS-CoV Vaccines and Therapeutics Based on the Receptor-Binding Domain. Viruses 2019, 11, 60.

Show more citation formats Show less citations formats

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Related Articles

Article Metrics

Article Access Statistics

1

Comments

[Return to top]
Viruses EISSN 1999-4915 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top